Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?

被引：137

作者：

Li, Naishi ^{[1
,2
]}

Fu, Jingyuan ^{[3
]}

Koonen, Debby P. ^{[1
]}

Kuivenhoven, Jan Albert ^{[1
]}

Snieder, Harold ^{[4
]}

Hofker, Marten H. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Mol Genet, Groningen, Netherlands

[2] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Endocrinol,Key Lab Endocrinol,Minist Hlth, Beijing, Peoples R China

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands

[4] Univ Groningen, Dept Epidemiol, Univ Med Ctr Groningen, Genet Epidemiol & Bioinformat Unit, Groningen, Netherlands

来源：

ATHEROSCLEROSIS | 2014年 / 233卷 / 01期

关键词：

HDL-cholesterol; Triglycerides; Insulin resistance; Dyslipidemia; TYPE-2; DIABETES-MELLITUS; LIFE-STYLE INTERVENTION; CORONARY-HEART-DISEASE; HEPATIC LIPASE GENE; LIPOPROTEIN-LIPASE; MENDELIAN RANDOMIZATION; GLUCOSE-METABOLISM; FOLLOW-UP; CHOLESTEROL; SENSITIVITY;

D O I：

10.1016/j.atherosclerosis.2013.12.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Insulin resistance often occurs with dyslipidemia as part of the metabolic syndrome and the current dominant paradigm is that insulin resistance leads to dyslipidemia. However, dyslipidemia may also cause insulin resistance; this was postulated 30 years ago, but has never been substantiated. Establishing whether dyslipidemia plays a causal role in the etiology of insulin resistance is important since it could reveal new avenues for combating type 2 diabetes. In this review we summarize recent evidence from epidemiological, genetic and intervention studies to re-address this old hypothesis. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：130 / 138

页数：9

共 84 条

[71] Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate [J].

Tenenbaum, A ;

Fisman, EZ ;

Boyko, V ;

Benderly, M ;

Tanne, D ;

Haim, M ;

Matas, Z ;

Motro, M ;

Behar, S .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (07) :737-741

[72] Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease [J].

Tenenbaum, A ;

Motro, M ;

Fisman, EZ ;

Schwammenthal, E ;

Adler, Y ;

Goldenberg, I ;

Leor, J ;

Boyko, V ;

Mandelzweig, L ;

Behar, S .

CIRCULATION, 2004, 109 (18) :2197-2202

[73] Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes [J].

Tenenbaum, Helena ;

Behar, Solomon ;

Boyko, Valentina ;

Adler, Yehuda ;

Fisman, Enrique Z. ;

Tanne, David ;

Lapidot, Mordechai ;

Schwarnmenthal, Ehud ;

Feinberg, Micha ;

Matas, Zipora ;

Motro, Michael ;

Tenenbaum, Alexander .

ATHEROSCLEROSIS, 2007, 194 (01) :265-271

[74] Biological, clinical and population relevance of 95 loci for blood lipids [J].

Teslovich, Tanya M. ;

Musunuru, Kiran ;

Smith, Albert V. ;

Edmondson, Andrew C. ;

Stylianou, Ioannis M. ;

Koseki, Masahiro ;

Pirruccello, James P. ;

Ripatti, Samuli ;

Chasman, Daniel I. ;

Willer, Cristen J. ;

Johansen, Christopher T. ;

Fouchier, Sigrid W. ;

Isaacs, Aaron ;

Peloso, Gina M. ;

Barbalic, Maja ;

Ricketts, Sally L. ;

Bis, Joshua C. ;

Aulchenko, Yurii S. ;

Thorleifsson, Gudmar ;

Feitosa, Mary F. ;

Chambers, John ;

Orho-Melander, Marju ;

Melander, Olle ;

Johnson, Toby ;

Li, Xiaohui ;

Guo, Xiuqing ;

Li, Mingyao ;

Cho, Yoon Shin ;

Go, Min Jin ;

Kim, Young Jin ;

Lee, Jong-Young ;

Park, Taesung ;

Kim, Kyunga ;

Sim, Xueling ;

Ong, Rick Twee-Hee ;

Croteau-Chonka, Damien C. ;

Lange, Leslie A. ;

Smith, Joshua D. ;

Song, Kijoung ;

Zhao, Jing Hua ;

Yuan, Xin ;

Luan, Jian'an ;

Lamina, Claudia ;

Ziegler, Andreas ;

Zhang, Weihua ;

Zee, Robert Y. L. ;

Wright, Alan F. ;

Witteman, Jacqueline C. M. ;

Wilson, James F. ;

Willemsen, Gonneke .

NATURE, 2010, 466 (7307) :707-713

[75] Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. [J].

Tuomilehto, J ;

Lindström, J ;

Eriksson, JG ;

Valle, TT ;

Hamalainen, H ;

Ilanne-Parikka, P ;

Keinanen-Kiukaanniemi, S ;

Laakso, M ;

Louheranta, A ;

Rastas, M ;

Salminen, V ;

Uusitupa, M ;

Aunola, S ;

Cepaitis, Z ;

Moltchanov, V ;

Hakumaki, M ;

Mannelin, M ;

Martikkala, V ;

Sundvall, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (18) :1343-1350

[76] LIPOTOXICITY IN THE PATHOGENESIS OF OBESITY-DEPENDENT NIDDM - GENETIC AND CLINICAL IMPLICATIONS [J].

UNGER, RH .

DIABETES, 1995, 44 (08) :863-870

[77] Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity [J].

Unger, Roger H. ;

Scherer, Philipp E. .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2010, 21 (06) :345-352

[78] Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic β-Cell Dysfunction [J].

Vergeer, Menno ;

Brunham, Liam R. ;

Koetsveld, Joris ;

Kruit, Janine K. ;

Verchere, C. Bruce ;

Kastelein, John J. P. ;

Hayden, Michael R. ;

Stroes, Erik S. G. .

DIABETES CARE, 2010, 33 (04) :869-874

[79] Differential diagnosis of familial high density lipoprotein deficiency syndromes [J].

von Eckardstein, Arnold .

ATHEROSCLEROSIS, 2006, 186 (02) :231-239

[80] Frail HDLs and Stiff Arteries in Type 2 Diabetes in Juveniles [J].

von Eckardstein, Arnold ;

Nofer, Jerzy-Roch .

DIABETES, 2013, 62 (08) :2662-2664

← 1 2 3 4 5 6 7 8 9 →